New Discovery: How Body Naturally Shuts Down Inflammation – Potential for Chronic Disease Treatments

Scientists have identified a natural process within the human body that appears to regulate and ultimately shut down inflammation, a discovery with potentially far-reaching implications for the treatment of chronic diseases. The research, conducted at University College London (UCL), details how the body controls the inflammatory response, offering a recent target for therapies aimed at conditions like arthritis, heart disease, and diabetes. Until now, the mechanisms governing the transition from active immune response to healing have remained largely unclear.

The Body’s Natural ‘Brake’ on Inflammation

Inflammation is a crucial defense mechanism, protecting us from infection and injury. However, when inflammation persists unchecked, it can contribute to a host of serious health problems. The UCL study, published in Nature Communications, pinpoints small, fat-based molecules called epoxy-oxylipins as key regulators of the immune response. These molecules appear to prevent the accumulation of intermediate monocytes – a type of white blood cell – which are strongly associated with chronic inflammation and subsequent tissue damage. More details on the discovery are available from UCL News.

Researchers conducted a controlled experiment involving healthy volunteers. Participants received a small injection of UV-killed E. Coli bacteria in the forearm, triggering a localized inflammatory response – characterized by pain, redness, heat, and swelling – mimicking what occurs after infection or injury. The volunteers were then divided into two groups: a prophylactic arm, treated before inflammation began, and a therapeutic arm, treated after inflammation had started.

How the Study Worked: Prophylactic vs. Therapeutic Approaches

In both groups, participants received either a drug called GSK2256294 or a placebo. GSK2256294 works by blocking an enzyme called soluble epoxide hydrolase (sEH), which normally breaks down epoxy-oxylipins. By blocking sEH, the researchers aimed to increase levels of these protective molecules. The prophylactic arm, consisting of 24 volunteers (12 receiving the drug, 12 receiving a placebo), was treated two hours before the inflammatory response began, to test whether boosting epoxy-oxylipins early could prevent harmful immune changes. The therapeutic arm, similarly with 24 volunteers (12 treated, 12 placebo), received the drug four hours after inflammation had started, simulating a real-world treatment scenario where intervention occurs after symptoms appear.

The results showed that blocking sEH consistently increased epoxy-oxylipin levels in both groups. Participants who received the drug experienced faster pain resolution and significantly lower levels of intermediate monocytes in both their blood and the affected tissue. Interestingly, the medication did not significantly alter visible symptoms like redness or swelling, suggesting its primary effect is on the underlying immune processes rather than the outward manifestations of inflammation.

A Specific Lipid, 12,13-EpOME, Plays a Key Role

Further investigation revealed that a specific epoxy-oxylipin, 12,13-EpOME, appears to suppress a protein signaling pathway known as p38 MAPK. This pathway is known to drive the transformation of monocytes into the inflammatory intermediate form. Laboratory experiments, coupled with additional testing in volunteers who also received a p38 blocking drug, confirmed this mechanism of action. ScienceDaily provides additional coverage of this discovery.

“Our findings reveal a natural pathway that limits harmful immune cell expansion and helps calm inflammation more quickly,” explained Dr. Olivia Bracken, first author of the study from the UCL Department of Ageing, Rheumatology and Regenerative Medicine. “Targeting this mechanism could lead to safer treatments that restore immune balance without suppressing overall immunity.”

Implications for Chronic Inflammatory Diseases

Professor Derek Gilroy, the corresponding author from the UCL Division of Medicine, added, “Here’s the first study to map epoxy-oxylipin activity in humans during inflammation. By boosting these protective fat molecules, we could design safer treatments for diseases driven by chronic inflammation.” He also highlighted the practical advantage of using a drug already approved for human use, potentially allowing for faster repurposing to treat flares in chronic inflammatory conditions, an area currently lacking effective therapies.

The researchers initially investigated epoxy-oxylipins based on previous animal studies suggesting their anti-inflammatory and pain-reducing properties. However, their role in human biology had not been fully understood. Unlike well-known inflammatory signals like histamine and cytokines, epoxy-oxylipins belong to a less-studied pathway that researchers hypothesized might naturally quiet the immune system. Genetic Engineering and Biotechnology News offers further insights into the immune-regulating lipid signals.

What’s Next: Clinical Trials and Potential Therapies

The findings pave the way for clinical trials to evaluate sEH inhibitors as potential treatments for diseases such as rheumatoid arthritis and cardiovascular disease. Dr. Bracken explained, “For instance, rheumatoid arthritis is a condition in which the immune system attacks the cells that line your joints. SEH inhibitors could be trialled alongside existing medications to investigate if they can help prevent or slow down joint damage incurred by the condition.” Arthritis UK, which funded the study, expressed excitement about the research and its potential to lead to new pain management options for people living with arthritis.

The research team emphasizes that this is a foundational step. Further studies are needed to fully understand the long-term effects of modulating epoxy-oxylipin levels and to identify the optimal dosage and treatment strategies. The focus will now shift towards translating these findings into tangible benefits for patients suffering from chronic inflammatory diseases. The process will involve rigorous clinical trials, careful monitoring of patient outcomes, and ongoing refinement of therapeutic approaches.